FluoGuide
48,7
SEK
+1,56 %
FLUO
First North Stockholm
Medical Equipment & Services
Health Care
Mindre end 1K følgere
+1,56%
+24,39%
+39,94%
+27,15%
+16,51%
-22,45%
-41,95%
+520,01%
+443,21%
FluoGuide er en dansk virksomhed, der er aktiv inden for medicinsk teknologi. Virksomhedens forretningsfokus findes i forskning og udvikling af behandlinger mod forskellige former for kræft, med størst fokus på udvikling af produkter, der styrer kirurgiske indgreb. Produkterne binder sig til kræftcellerne, som så lyser op og er beregnet til at blive brugt til præcist at fjerne skadelige svulster i patientens væv.
Læs mereMarkedsværdi
663,3 mio. SEK
Aktieomsætning
125,77 t SEK
Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
Finanskalender
27.2
2025
Årsrapport '24
27.3
2025
Generalforsamling '25
28.5
2025
Delårsrapport Q1'25
ViserAlle indholdstyper
FluoGuide A/S receives approval for phase II trial in head and neck cancer
Redeye: Fluoguide Q3 2024 - Gearing up for high-impact catalysts in 2025e
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
FluoGuide A/S publishes interim report for the period January – September 2024
Publication of positive phase II clinical data for FG001 in patients with head and neck cancer
FluoGuide A/S issue warrants to board member, CMO and CFO
Roger Gunnarsson resigns as board member due to return to a full-time investment banking career, which precludes him from holding board position in FluoGuide
FluoGuide A/S submits Clinical Trial Application for phase II trial in head and neck cancer
Redeye: Fluoguide Q2 2024 - Following the plan
FluoGuide A/S publishes interim report for the period January – June 2024
FluoGuide appoints Jens Ellrich as Chief Medical Officer
FluoGuide has completed a directed share issue to existing and new investors raising proceeds of SEK 60 million
FluoGuide intends to carry out a directed share issue of approximately SEK 60 million
Redeye: Fluoguide Q1 2024 - Preparing for next steps
FluoGuide A/S publishes interim report for the period January – March 2024
FluoGuide selects laser system for photothermal cancer therapy with FG001
Dagens aktienyheder 21/03: Green Hydrogen Systems, Hafnia, TORM, MapsPeople og FluoGuide A/S
Fluoguide: Wrap up from interview with CEO Morten Albrechtsen
Minutes from Annual General Meeting in FluoGuide A/S
